Acute effects of intravenous administration of pamidronate in patients with osteoporosis

Journal of Korean Medical Science

Volumn 25, Issue 9, 2010, Pages 1277-1283

  Lim, Mie Jin ^a   Kwon, Seong Ryul ^a   Park, Shin Goo ^a   Park, Won ^a  

^a Inha University Hospital   (South Korea)

Author keywords

Acute phase reaction; Diphosphonates; Osteoporosis; Pamidronate

Indexed keywords

ACUTE PHASE PROTEIN; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; C REACTIVE PROTEIN; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 6; MESSENGER RNA; PAMIDRONIC ACID; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; BLOOD CELL; DRUG EFFECT; FEMALE; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BLOOD CELLS; BONE DENSITY CONSERVATION AGENTS; C-REACTIVE PROTEIN; CALCIUM; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956503722     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.9.1277     Document Type: Article

References (25)

1. Olson K, van Poznak C. Significance and impact of bisphosphate-induced acute phase responses. J Oncol Pharm Pract 2007; 13: 223-9.
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88 (12 Suppl): 2961-78.
3. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s-30s.
4. Adami A, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-31.
5. Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Meijer H, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP. APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 1980; 23: 1193-204.
6. Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, Löwik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956-62.
7. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996; 18: 133-9.
8. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386-92.
9. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-4.
10. Leib ES, Lewiecki EM, Binkley N, Hamdy RC; International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: 1-6.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
12. Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, Aarden LA, Yap SH. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155: 112-7.
13. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139: 101-11.
14. Green AE, Lissina A, Hutchinson SL, Hewitt RE, Temple B, James D, Boulter JM, Price DA, Sewell AK. Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin. Clin Exp Immunol 2004; 136: 472-82.
15. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 2001; 166: 5508-14.
16. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235-42.
17. Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol 2007; 18: 201-2.
18. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003; 23: 649-54.
19. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
20. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-7.
21. Chae BN, Hong EG, Lee SK, Chung YS, Lee KW, Kim HM. Cyclic pamidronate infusion in primary osteoporotic women. J Korean Soc Endocrinol 2001; 16: 221-30.
22. Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite AE. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 2006; 146: 371-80.
23. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001; 166: 2276--82.
24. Alonci A, Allegra A, Bellomo G, Quartarone E, Oteri G, Nastro E, Cicciù D, De Ponte FS, Musolino C. Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma 2007; 48: 1852-4.
25. Shenker NG, Jawad AS. Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford) 2007; 46: 1049-51.